Arcturus Therapeutics Holdings Inc
ARCT12.193USD
-0.107-0.87%
Horário de mercado （ET）Cotações atrasadas em 15 min
330.68MValor de mercado
PerdaP/L TTM
Mais detalhes de Arcturus Therapeutics Holdings Inc Empresa
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Informações da empresa
Código da empresaARCT
Nome da EmpresaArcturus Therapeutics Holdings Inc
Data de listagemMay 22, 2013
CEOMr. Joseph E. Payne
Número de funcionários174
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 22
Endereço10628 Science Center Dr Ste 250
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92121-1132
Telefone18589002660
Sitehttps://arcturusrx.com/
Código da empresaARCT
Data de listagemMay 22, 2013
CEOMr. Joseph E. Payne
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Andrew H. (Andy) Sassine
Mr. Andrew H. (Andy) Sassine
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Federated Hermes Global Investment Management Corp.
17.31%
BlackRock Institutional Trust Company, N.A.
7.82%
Nikko Asset Management Co., Ltd.
6.76%
The Vanguard Group, Inc.
6.67%
ARK Investment Management LLC
6.32%
Other
55.12%
Investidores
Investidores
Proporção
Federated Hermes Global Investment Management Corp.
17.31%
BlackRock Institutional Trust Company, N.A.
7.82%
Nikko Asset Management Co., Ltd.
6.76%
The Vanguard Group, Inc.
6.67%
ARK Investment Management LLC
6.32%
Other
55.12%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
43.62%
Investment Advisor
28.78%
Hedge Fund
13.66%
Individual Investor
7.88%
Research Firm
5.21%
Insurance Company
1.01%
Pension Fund
0.52%
Bank and Trust
0.30%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
391
27.00M
99.57%
-3.36M
2025Q1
403
27.75M
102.37%
-3.11M
2024Q4
400
27.43M
101.26%
-2.26M
2024Q3
404
26.95M
99.66%
-3.33M
2024Q2
409
27.79M
102.77%
-2.68M
2024Q1
391
28.99M
107.82%
+144.88K
2023Q4
376
27.09M
101.05%
-1.26M
2023Q3
373
26.77M
100.23%
-170.02K
2023Q2
355
26.49M
99.74%
-2.09M
2023Q1
361
26.10M
98.32%
-2.45M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Federated Hermes Global Investment Management Corp.
4.69M
17.31%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
7.82%
-29.89K
-1.39%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
1.93M
7.1%
-138.97K
-6.73%
Mar 31, 2025
The Vanguard Group, Inc.
1.74M
6.43%
+64.37K
+3.83%
Mar 31, 2025
ARK Investment Management LLC
2.01M
7.41%
+74.63K
+3.86%
Mar 31, 2025
Payne (Joseph E)
1.48M
5.46%
--
--
Apr 08, 2025
State Street Global Advisors (US)
1.28M
4.72%
-45.71K
-3.45%
Mar 31, 2025
Balyasny Asset Management LP
938.19K
3.46%
+389.43K
+70.97%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
825.77K
3.04%
-23.32K
-2.75%
Mar 31, 2025
Woodline Partners LP
780.44K
2.88%
-26.47K
-3.28%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ARK Genomic Revolution ETF
2.14%
WisdomTree BioRevolution Fund
1.67%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
iShares Genomics Immunology and Healthcare ETF
0.74%
AXS Green Alpha ETF
0.54%
Global X Genomics & Biotechnology ETF
0.41%
ALPS Medical Breakthroughs ETF
0.24%
SPDR S&P Biotech ETF
0.12%
iShares Micro-Cap ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
Ver Mais
ARK Genomic Revolution ETF
Proporção2.14%
WisdomTree BioRevolution Fund
Proporção1.67%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.93%
iShares Genomics Immunology and Healthcare ETF
Proporção0.74%
AXS Green Alpha ETF
Proporção0.54%
Global X Genomics & Biotechnology ETF
Proporção0.41%
ALPS Medical Breakthroughs ETF
Proporção0.24%
SPDR S&P Biotech ETF
Proporção0.12%
iShares Micro-Cap ETF
Proporção0.07%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.07%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
